Stock 6090 HUMAN METABOLOME TECHNOLOGIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Human Metabolome Technologies, Inc.

Equities

6090

JP3794530000

Biotechnology & Medical Research

Market Closed - Japan Exchange
Other stock markets
 01:37:07 2024-04-26 am EDT 		5-day change 1st Jan Change
655 JPY -1.06% Intraday chart for Human Metabolome Technologies, Inc. -2.38% +2.34%
Feb. 14 Human Metabolome Technologies, Inc. Provides Dividend Guidance for the Year Ending June 2024 CI
2023 Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 30, 2024 CI

Valuation

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Capitalization 1 10,813 5,391 7,405 5,104 4,307 4,424
Enterprise Value (EV) 1 9,392 4,371 6,204 4,011 3,035 2,994
P/E ratio -68.9 x -11.5 x -157 x 87.9 x 16.1 x 15.5 x
Yield - - - - - 1.34%
Capitalization / Revenue 11.5 x 6.43 x 6.62 x 4.54 x 3.52 x 3.41 x
EV / Revenue 10 x 5.21 x 5.55 x 3.57 x 2.48 x 2.31 x
EV / EBITDA -117 x -13.2 x 207 x 42.2 x 11.9 x 10.3 x
EV / FCF -40.3 x -16.9 x 38.7 x -67.3 x 20.4 x 36.2 x
FCF Yield -2.48% -5.93% 2.58% -1.49% 4.91% 2.76%
Price to Book 6.16 x 4.44 x 6.11 x 4.05 x 2.9 x 2.5 x
Nbr of stocks (in thousands) 5,848 5,854 5,887 5,900 5,900 5,907
Reference price 2 1,849 921.0 1,258 865.0 730.0 749.0
Announcement Date 6/26/18 9/25/19 9/29/20 9/27/21 9/26/22 9/25/23
1JPY in Million2JPY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net sales 1 938 839 1,118 1,124 1,223 1,299
EBITDA 1 -80 -332 30 95 255 291
EBIT 1 -141 -396 -17 40 191 211
Operating Margin -15.03% -47.2% -1.52% 3.56% 15.62% 16.24%
Earnings before Tax (EBT) 1 -149 -465 -24 51 262 237
Net income 1 -156 -469 -47 58 267 285
Net margin -16.63% -55.9% -4.2% 5.16% 21.83% 21.94%
EPS 2 -26.83 -80.16 -8.018 9.837 45.25 48.26
Free Cash Flow 1 -233.1 -259.1 160.4 -59.62 149.1 82.62
FCF margin -24.85% -30.88% 14.34% -5.3% 12.19% 6.36%
FCF Conversion (EBITDA) - - 534.58% - 58.48% 28.39%
FCF Conversion (Net income) - - - - 55.85% 28.99%
Dividend per Share - - - - - 10.00
Announcement Date 6/26/18 9/25/19 9/29/20 9/27/21 9/26/22 9/25/23
1JPY in Million2JPY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: June 2020 S1 2021 S1 2022 Q1 2022 S1 2022 Q3 2023 Q1 2023 S1 2023 Q3 2024 Q1 2024 S1
Net sales 1 454 537 173 533 477 262 610 465 235 632
EBITDA - - - - - - - - - -
EBIT 1 -123 2 -44 76 192 1 84 178 -30 71
Operating Margin -27.09% 0.37% -25.43% 14.26% 40.25% 0.38% 13.77% 38.28% -12.77% 11.23%
Earnings before Tax (EBT) 1 -116 1 -37 88 223 6 90 179 -12 89
Net income 1 -118 -7 -48 82 199 -17 74 154 -38 71
Net margin -25.99% -1.3% -27.75% 15.38% 41.72% -6.49% 12.13% 33.12% -16.17% 11.23%
EPS 2 -20.26 -1.240 -8.280 13.92 33.72 -2.980 12.56 26.15 -6.470 12.02
Dividend per Share - - - - - - - - - -
Announcement Date 2/7/20 2/12/21 11/12/21 2/14/22 5/13/22 11/11/22 2/14/23 5/12/23 11/10/23 2/14/24
1JPY in Million2JPY
Estimates

Balance Sheet Analysis

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 1,421 1,020 1,201 1,093 1,272 1,430
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -233 -259 160 -59.6 149 82.6
ROE (net income / shareholders' equity) -8.64% -22.5% -3.87% 4.69% 19.5% 17.5%
ROA (Net income/ Total Assets) -4.47% -12.9% -0.73% 1.58% 6.47% 6.05%
Assets 1 3,490 3,640 6,426 3,667 4,128 4,710
Book Value Per Share 2 300.0 207.0 206.0 213.0 252.0 300.0
Cash Flow per Share 2 216.0 162.0 190.0 211.0 255.0 280.0
Capex 1 85 114 34 26 142 98
Capex / Sales 9.06% 13.54% 3.04% 2.31% 11.61% 7.54%
Announcement Date 6/26/18 9/25/19 9/29/20 9/27/21 9/26/22 9/25/23
1JPY in Million2JPY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
HUMAN METABOLOME TECHNOLOGIES, INC. Stock Human Metabolome Technologies, Inc.
+2.34% 24.61M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 6090 Stock
  4. Financials Human Metabolome Technologies, Inc.